RecruitingNCT05665556

REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)

REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE) at the National Institute of Medical Sciences and Nutrition Salvador Zubirán

Sponsor

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Enrollment

170 participants

Start Date

Dec 15, 2022

Study Type

OBSERVATIONAL

Conditions

Pulmonary Arterial Hypertension Connective Tissue Diseases

Summary

The RECONNECTIVE Registry is an observational single center study, focused on the subgroup of precapillary pulmonary hypertension related to connective tissue diseases. All patients will have hemodynamic confirmation by right heart catheterization and will be follow-up for at least 5 years from admission. All patients diagnosed with Group I Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) and Group IV Pulmonary Hypertension (PH) with CTD will be included. The purpose of the registry is to learn and understand the clinical outcomes and natural history of the pulmonary arterial hypertension in this subgroup of patients to improve the medical care and treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This registry study tracks patients with pulmonary arterial hypertension (PAH) — a condition involving high blood pressure in the arteries supplying the lungs — that is caused by or associated with a connective tissue disease (such as lupus, scleroderma, or rheumatoid arthritis). The goal is to better understand disease progression and treatment outcomes in this specific patient group. **You may be eligible if...** - You have been diagnosed with pulmonary arterial hypertension (Group I PAH) linked to a connective tissue disease - OR you have pulmonary hypertension due to chronic blood clots (Group IV) associated with a connective tissue disease, confirmed after at least 3 months of blood thinning treatment - Your connective tissue disease has been diagnosed using standard rheumatology criteria - Your PAH has been confirmed by a right heart catheterization (a definitive diagnostic procedure) **You may NOT be eligible if...** - Your pulmonary hypertension belongs to Groups II, III, or V (e.g., caused by left heart disease, lung disease, or unclear/multifactorial causes) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.